ArticleBMC neuroscience2025
Hippocampal functional imaging-derived radiomics features for diagnosing cognitively impaired patients with Parkinson's disease.
Article in BMC neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The application of radiomics in the diagnosis and evaluation of cognitive impairment related to neurological diseases.Frontiers in neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThe aim of this retrospective study was to investigate whether radiomics features derived from hippocampal functional imaging can effectively differentiate cognitively impaired patients from cognitively preserved patients with Parkinson's disease (PD).
methodsThe study included a total of 89 clinically definite PD patients, comprising 55 who werecognitively impaired and 34 who were cognitively preserved. All participants underwent functional magnetic resonance imaging and clinical assessments. Preprocessed functional data were utilized to derive the amplitude of the low-frequency fluctuations (ALFF), regional homogeneity (ReHo), voxel-mirrored homotopic connectivity (VMHC), and degree centrality (DC). A standardized set of radiomics features was subsequently extracted from the bilateral hippocampi, resulting in a total of 819 features. Following feature selection, the radiomics score (rad-score) and logistic regression (LR) models were trained. Additionally, the Shapley additive explanations (SHAP) algorithm was employed to elucidate and interpret the predictions made by the LR models. Finally, the relationships between the radiomics features derived from hippocampal functional imaging and the scores of the clinical measures were explored to assess their clinical significance.
resultsThe rad-score and LR algorithm models constructed using a combination of wavelet features extracted from ReHo and VMHC data exhibited superior classification efficiency. These models demonstrated exceptional accuracy, sensitivity, and specificity in distinguishing cognitively impaired PD patients (CI-PD) from cognitively preserved PD (CP-PD) patients, with values of 0.889, 0.900, and 0.882, respectively. Furthermore, SHAP values indicated that wavelet features derived from ReHo and VMHC were critical for classifying CI-PD patients. Importantly, our findings revealed significant associations between radiomics wavelet features and scores on the Hamilton Anxiety Scale, Non-Motor Symptom Scale, and Montreal Cognitive Assessment in CI-PD patients (P < 0.05, with Bonferroni correction).
conclusionsOur novel rad-score model and LR model, which utilize radiomics features derived from hippocampal functional imaging, have demonstrated their value in diagnosing CI-PDpatients. These models can enhance the accuracy and efficiency of functional MRI diagnosis, suggesting potential clinical applications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.